Table 2.

Differences in sleep disturbance symptoms, daytime functioning, and psychiatric aspects between control (placebo) and test (alpha-s1 casein hydrolysate (ACH)) phases.

Variables	Placebo			ACH			p-Value †
							Group	Time	Group × Time
Pittsburgh Sleep Quality Index
Week 0	10.14	±	0.42	9.79	±	0.42
Week 2	8.23	±	0.42	8.79	±	0.43
Week 4	8.41	±	0.42	8.51	±	0.43	0.668	<0.001 **	0.211
Insomnia Severity Index
Week 0	12.15	±	0.73	12.08	±	0.73
Week 2	9.75	±	0.73	10.50	±	0.74
Week 4	9.44	±	0.73	10.04	±	0.74	0.406	<0.001 **	0.523
Epworth Sleepiness Scale
Week 0	6.30	±	0.58	6.72	±	0.58
Week 2	6.10	±	0.58	5.91	±	0.59
Week 4	6.02	±	0.58	5.67	±	0.59	0.920	0.039	0.324
Fatigue Severity Scale
Week 0	31.60	±	1.64	32.55	±	1.65
Week 2	31.00	±	1.65	32.64	±	1.67
Week 4	30.67	±	1.65	31.29	±	1.67	0.276	0.462	0.854
Beck Depression Inventory
Week 0	11.65	±	1.25	12.37	±	1.26
Week 2	11.49	±	1.26	12.28	±	1.27
Week 4	10.41	±	1.26	10.79	±	1.27	0.464	0.008 *	0.912
Beck Anxiety Inventory
Week 0	8.04	±	1.11	7.71	±	1.11
Week 2	8.41	±	1.11	7.72	±	1.12
Week 4	7.70	±	1.11	7.09	±	1.12	0.363	0.362	0.924

Data are least square (LS) mean ± standard error of mean (SEM). ^† p-value, linear mixed-effects model was used to analyze the effects of group, time, and group × time for four weeks. * q-value < 0.05 and ** q-value < 0.01, Storey’s positive false discovery rate (pFDR) was calculated to account for multiple testing.